Innovation and compliance are not diametrically opposed.
作者信息
Raab G K
机构信息
Genentech, Inc., South San Francisco, California 94080.
出版信息
Qual Assur. 1994 Mar;3(1):2-8.
PMID:7804614
Abstract
摘要
相似文献
1
Innovation and compliance are not diametrically opposed.创新与合规并非截然对立。
Qual Assur. 1994 Mar;3(1):2-8.
2
How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation.药品安全法规的变化如何影响制药和生物技术公司的创新投资方式。
Health Aff (Millwood). 2006 Sep-Oct;25(5):1309-17. doi: 10.1377/hlthaff.25.5.1309.
3
The use of total quality principles to achieve regulatory compliance in research laboratories.运用全面质量原则在研究实验室中实现法规遵从。
Qual Assur. 1995 Mar;4(1):34-40.
4
Study critiques corporate control of trials.该研究批评了企业对试验的控制。
Nat Biotechnol. 2002 Dec;20(12):1180. doi: 10.1038/nbt1202-1180.
5
Navigating biotechnology's new fiscal opportunities.把握生物技术领域的新财政机遇。
Nat Biotechnol. 1998 May;16 Suppl:51-3. doi: 10.1038/5423.
6
Medical innovation meets healthcare reform.医学创新与医疗改革相遇。
Health Prog. 1994 Jul-Aug;75(6):14-6, 32.
7
US health reform and value: hit or miss?美国医疗改革与价值：成功还是失败？
Expert Rev Pharmacoecon Outcomes Res. 2010 Oct;10(5):477-80. doi: 10.1586/erp.10.40.
8
Investing in risk management.投资风险管理。
Nat Biotechnol. 1997 Jan;15(1):88-9. doi: 10.1038/nbt0197-88.
9
The regulation of biopharmaceuticals.生物制药的监管
Qual Assur. 1993 Mar-Jun;2(1-2):147-51.
10
FDA state of affairs.
Qual Assur. 1993 Mar-Jun;2(1-2):156-61.
Zotero 插件